OXYGENTA PHARMACEUTICAL LIMITE (OXYGENTAPH.BO)
INR 93.8
(1.99%)
INR 93.8
(1.99%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -146.25 Million | -31.16 Million | -26 Million | -33.82 Million | -76.47 Million | -85.27 Million |
| Net Income | -34.79 Million | -115.7 Million | -6.1 Million | 29.29 Million | -57.88 Million | -32.54 Million |
| Depreciation & Amortization | 26.6 Million | 20.51 Million | 15.91 Million | 11.95 Million | 9.98 Million | 10.18 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -34.85 Million | 64.03 Million | -35.81 Million | -75.08 Million | 11.26 Million | -62.91 Million |
| Other non-cash items | -22.27 Million | -40.97 Million | 73.73 Million | 31.57 Million | -29.2 Million | 80.05 Million |
| Investing Cash Flow | -41.05 Million | -96.44 Million | -49.45 Million | -67.41 Million | -5.2 Million | -5.68 Million |
| Investments in PPE | -41.05 Million | -96.44 Million | -49.45 Million | -67.41 Million | -5.2 Million | -5.68 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 187.25 Million | 127.11 Million | 72.56 Million | 104.5 Million | 42.82 Million | 91.03 Million |
| Debt repayment | -107.59 Million | -127.11 Million | -32.56 Million | -104.5 Million | -42.82 Million | -91.03 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 294.85 Million | - | 40 Million | - | - | - |
| Other Financing Activities | - | -203.00 | -27.00 | -283.00 | -37.00 | 182.06 Million |
| Accounts receivables | 31.95 Million | -85.83 Million | 731.78 Thousand | -9.44 Million | 6.98 Million | -6.41 Million |
| Accounts payables | -39.57 Million | 212.06 Million | -90.94 Million | 80.39 Million | -8.43 Million | -15.49 Million |
| Inventory | -20.11 Million | -44.22 Million | 48.3 Million | -78.6 Million | 10.78 Million | -37.76 Million |
| Other working capital | -7.13 Million | -17.97 Million | 6.09 Million | -67.42 Million | 1.93 Million | -3.23 Million |
| Cash at beginning of period | 1.06 Million | 1.55 Million | 4.45 Million | 1.18 Million | 186.48 Thousand | 113.73 Thousand |
| Cash at end of period | 1 Million | 1.06 Million | 1.55 Million | 4.45 Million | 1.18 Million | 186.48 Thousand |
| Capital Expenditure | -41.05 Million | -96.44 Million | -49.45 Million | -67.41 Million | -5.2 Million | -5.68 Million |
| Effect of forex changes on cash | - | 1.00 | 2.00 | -1.00 | 39.85 Million | - |
| Net cash flow / Change in cash | -54.17 Thousand | -494.62 Thousand | -2.89 Million | 3.26 Million | 996.73 Thousand | 72.74 Thousand |
| Free Cash Flow | -187.31 Million | -127.61 Million | -75.45 Million | -101.23 Million | -81.67 Million | -90.95 Million |
| Breakdown | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 FY |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -34.79 Million | -33.55 Million | -31.6 Million | -45.58 Million | -42.9 Million | -115.7 Million |
| Depreciation & Amortization | 26.6 Million | 6.88 Million | 8.34 Million | 5 Million | 8.51 Million | 20.51 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -34.85 Million | - | - | - | - | 64.03 Million |
| Other non-cash items | -22.27 Million | 40.44 Million | -8.34 Million | -5 Million | -8.51 Million | -40.97 Million |
| Investing Cash Flow | -41.05 Million | - | - | - | - | -96.44 Million |
| Investments in PPE | -41.05 Million | - | - | - | - | -96.44 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 187.25 Million | - | - | - | - | 127.11 Million |
| Debt repayment | -107.59 Million | - | - | - | - | -127.11 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 294.85 Million | - | - | - | - | - |
| Other Financing Activities | - | - | - | - | - | -203.00 |
| Accounts receivables | 31.95 Million | - | - | - | - | -85.83 Million |
| Accounts payables | -39.57 Million | - | - | - | - | 212.06 Million |
| Inventory | -20.11 Million | - | - | - | - | -44.22 Million |
| Other working capital | -7.13 Million | - | - | - | - | -17.97 Million |
| Cash at beginning of period | 1.06 Million | 72 Thousand | 31.67 Million | 1.06 Million | 43.97 Million | 1.55 Million |
| Cash at end of period | 1 Million | 13.84 Million | 72 Thousand | -45.58 Million | 1.06 Million | 1.06 Million |
| Capital Expenditure | -41.05 Million | - | - | - | - | -96.44 Million |
| Effect of forex changes on cash | - | - | - | - | - | 1.00 |
| Net cash flow / Change in cash | -54.17 Thousand | 13.77 Million | -31.6 Million | -46.65 Million | -42.9 Million | -494.62 Thousand |
| Free Cash Flow | -187.31 Million | 13.77 Million | -31.6 Million | -45.58 Million | -42.9 Million | -127.61 Million |
SWF
RAMRAT
SGML
63MOONS
6805
4251